E-LIB Suche - Ergebnisse für: Hans Peter Grimm

1

Re‐estimation of drug‐specific amyloid removal parameters a..:

Mazer, Norman A ; Lott, Dominik ; Grimm, Hans Peter...
Alzheimer's & Dementia. 19 (2023) S12 - p. , 2023

Link: https://doi.org/10.1002/..

2

Delivery of the Brainshuttle™ amyloid-beta antibody fusion ..:

Grimm, Hans Peter ; Schumacher, Vanessa ; Schäfer, Martin...
mAbs. 15 (2023) 1 - p. , 2023

Link: https://doi.org/10.1080/..

3

Learn–confirm in model‐informed drug development: Assessing..:

Franssen, Linnea C. ; Swat, Maciej J. ; Kierzek, Andrzej M....
CPT: Pharmacometrics & Systems Pharmacology. 12 (2022) 2 - p. 139-143 , 2022

Link: https://doi.org/10.1002/..

4

In silico exploration of amyloid‐related imaging abnormalit..:

Aldea, Roxana ; Grimm, Hans Peter ; Gieschke, Ronald...
Alzheimer's & Dementia: Translational Research & Clinical Interventions. 8 (2022) 1 - p. , 2022

Link: https://doi.org/10.1002/..

5

Development of a quantitative semi‐mechanistic model of Alz..:

Mazer, Norman A. ; Hofmann, Carsten ; Lott, Dominik...
Alzheimer's & Dementia. 19 (2022) 6 - p. 2287-2297 , 2022

Link: https://doi.org/10.1002/..

6

Linking amyloid to clinical outcome: A quantitative semi‐me..:

Mazer, Norman A ; Hofmann, Carsten ; Lott, Dominik...
Alzheimer's & Dementia. 18 (2022) S3 - p. , 2022

Link: https://doi.org/10.1002/..

7

Dynamic Contrast-Enhanced Magnetic Resonance Imaging for th..:

Bordeau, Brandon M. ; Polli, Joseph Ryan ; Schweser, Ferdinand...
International Journal of Molecular Sciences. 23 (2022) 2 - p. 679 , 2022

Link: https://doi.org/10.3390/..

8

Industrial Perspective on the Benefits Realized From the FD..:

Galluppi, Gerald R. ; Brar, Satjit ; Caro, Luzelena...
Clinical Pharmacology & Therapeutics. 110 (2021) 5 - p. 1172-1175 , 2021

Link: https://doi.org/10.1002/..

9

Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics..:

Eigenmann, Miro Julian ; Karlsen, Tine Veronica ; Wagner, Marek...
Pharmaceutics. 13 (2021) 12 - p. 2105 , 2021

Link: https://doi.org/10.3390/..

10

Why does ARIA‐E appear bright? A quantitative model linking..:

Aldea, Roxana ; Grimm, Hans Peter ; Gieschke, Ronald...
Alzheimer's & Dementia. 16 (2020) S4 - p. , 2020

Link: https://doi.org/10.1002/..

11

PKPD Assessment of the Anti-CD20 Antibody Obinutuzumab in C..:

Grimm, Hans Peter ; Schick, Eginhard ; Hainzl, Dominik...
Journal of Pharmaceutical Sciences. 108 (2019) 11 - p. 3729-3736 , 2019

Link: https://doi.org/10.1016/..

12

Development of a Unified Dissolution and Precipitation Mode..:

Jakubiak, Paulina ; Wagner, Björn ; Grimm, Hans Peter...
Molecular Pharmaceutics. 13 (2016) 2 - p. 586-598 , 2016

Link: https://doi.org/10.1021/..

13

Potential errors in the volume of distribution estimation o..:

Richter, Wolfgang F. ; Grimm, Hans Peter ; Theil, Frank-Peter
Journal of Pharmacokinetics and Pharmacodynamics. 38 (2011) 5 - p. 581-593 , 2011

Link: https://doi.org/10.1007/..

14

Modelling of patient EMS exposure: Translating pharmacokine..:

Lavé, Thierry ; Paehler, Axel ; Grimm, Hans Peter..
Toxicology Letters. 190 (2009) 3 - p. 310-316 , 2009

Link: https://doi.org/10.1016/..

15

Gaining insights into the consequences of target-mediated d..:

Grimm, Hans Peter
Journal of Pharmacokinetics and Pharmacodynamics. 36 (2009) 5 - p. 407-420 , 2009

Link: https://doi.org/10.1007/..